Cartesian Therapeutics (NASDAQ:RNAC) Earns Buy Rating from HC Wainwright

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They presently have a $25.00 price objective on the stock. HC Wainwright‘s target price points to a potential upside of 296.83% from the company’s previous close.

RNAC has been the topic of several other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cartesian Therapeutics in a report on Wednesday, September 9th. Wedbush restated an “outperform” rating and set a $38.00 price target on shares of Cartesian Therapeutics in a report on Tuesday, August 18th. Zacks Research upgraded shares of Cartesian Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Needham & Company LLC restated a “buy” rating and issued a $40.00 price target on shares of Cartesian Therapeutics in a research report on Tuesday, September 29th. Finally, Wall Street Zen raised shares of Cartesian Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.60.

Read Our Latest Analysis on Cartesian Therapeutics

Cartesian Therapeutics Stock Up 2.9%

Shares of RNAC opened at $6.30 on Thursday. The stock’s 50-day moving average price is $6.97 and its two-hundred day moving average price is $7.61. Cartesian Therapeutics has a 12 month low of $5.60 and a 12 month high of $11.00.

Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.63. As a group, research analysts anticipate that Cartesian Therapeutics will post -2.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in RNAC. Bank of New York Mellon Corp bought a new stake in shares of Cartesian Therapeutics during the 2nd quarter valued at about $332,000. Renaissance Technologies LLC grew its stake in Cartesian Therapeutics by 63.7% during the first quarter. Renaissance Technologies LLC now owns 67,300 shares of the company’s stock worth $414,000 after purchasing an additional 26,200 shares during the period. Empowered Funds LLC bought a new stake in Cartesian Therapeutics in the third quarter worth approximately $180,000. Squarepoint Ops LLC increased its holdings in Cartesian Therapeutics by 0.7% in the second quarter. Squarepoint Ops LLC now owns 2,254,619 shares of the company’s stock worth $23,493,000 after purchasing an additional 16,133 shares in the last quarter. Finally, Sei Investments Co. bought a new stake in Cartesian Therapeutics in the first quarter worth approximately $78,000. 86.95% of the stock is owned by institutional investors.

Cartesian Therapeutics Company Profile

(Get Free Report)

Cartesian Therapeutics is a clinical-stage biotechnology company developing RNA-engineered cell therapies for autoimmune diseases and cancer. Its platform uses messenger RNA to program immune cells, including T cells, to recognize and target disease-associated cells. The company’s lead program, Descartes-08, is an autologous CAR T-cell therapy designed to target BCMA and being studied for generalized myasthenia gravis. Unlike gene-modified cell therapies that rely on permanent genetic changes, Cartesian’s approach uses RNA to produce temporary cell modifications.

Recommended Stories

Analyst Recommendations for Cartesian Therapeutics (NASDAQ:RNAC)

Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.